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Abstract
Background: Surgical placebos are controversial. This in-depth study explored the design, acceptability, and
feasibility issues relevant to designing a surgical placebo-controlled trial for the evaluation of the clinical and cost
effectiveness of arthroscopic lavage for the management of people with osteoarthritis of the knee in the UK.
Methods: Two surgeon focus groups at a UK national meeting for orthopaedic surgeons and one regional
surgeon focus group (41 surgeons); plenary discussion at a UK national meeting for orthopaedic anaesthetists (130
anaesthetists); three focus groups with anaesthetists (one national, two regional; 58 anaesthetists); two focus
groups with members of the patient organisation Arthritis Care (7 participants); telephone interviews with people
on consultant waiting lists from two UK regional centres (15 participants); interviews with Chairs of UK ethics
committees (6 individuals); postal surveys of members of the British Association of Surgeons of the Knee (382
surgeons) and members of the British Society of Orthopaedic Anaesthetists (398 anaesthetists); two centre pilot (49
patients assessed).
Results: There was widespread acceptance that evaluation of arthroscopic lavage had to be conducted with a
placebo control if scientific rigour was not to be compromised. The choice of placebo surgical procedure (three
small incisions) proved easier than the method of anaesthesia (general anaesthesia). General anaesthesia, while an
excellent mimic, was more intrusive and raised concerns among some stakeholders and caused extensive
discussion with local decision-makers when seeking formal approval for the pilot.
Patients were willing to participate in a pilot with a placebo arm; although some patients when allocated to
surgery became apprehensive about the possibility of receiving placebo, and withdrew. Placebo surgery was
undertaken successfully.
Conclusions: Our study illustrated the opposing and often strongly held opinions about surgical placebos, the
ethical issues underpinning this controversy, and the challenges that exist even when ethics committee approval
has been granted. It showed that a placebo-controlled trial could be conducted in principle, albeit with difficulty. It
also highlighted that not only does a placebo-controlled trial in surgery have to be ethically and scientifically
acceptable but that it also must be a feasible course of action. The place of placebo-controlled surgical trials more
generally is likely to be limited and require specific circumstances to be met. Suggested criteria are presented.
Trial registration number: The trial was assigned ISRCTN02328576 through http://controlled-trials.com/ in June
2006. The first patient was randomised to the pilot in July 2007.
* Correspondence: m.k.campbell@abdn.ac.uk
1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
Full list of author information is available at the end of the article
Campbell et al. Trials 2011, 12:50
http://www.trialsjournal.com/content/12/1/50 TRIALS
© 2011 Campbell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Background
The placebo-controlled trial is a widely accepted design
for evaluating pharmacological and device interventions.
There has, however, been considerable debate in the lit-
erature about the ethical acceptability of including a pla-
cebo in procedures such as surgery. Whilst the use of a
placebo in surgical trials is not new [1-8] the concept
remains highly controversial. Several commentators have
argued that placebo procedures are ethical for certain
trials of surgery [9], but others have argued strongly
that the use of surgical placebos cannot be justified as
any surgical procedure carries risks of harm that are
greater than those associated with no surgery [10,11].
The term “placebo” is commonly used to describe any
substance or procedure a patient accepts as medicine or
therapy, but which has no known mechanism other
than a patient’s belief in its value [12]. The aim of any
placebo is to maximise the mimic of the active interven-
tion (and its benefits) whilst minimising the risks asso-
ciated with it [13,14]. A range of interventions, from
dummy pills to surgical techniques, have been used as
placebos [14]. Within a surgical context, however, no
surgical placebo can be completely without the possibi-
lity of harm. This leads to particularly complex issues
when trying to design a surgical placebo-controlled trial.
In this paper we report on a study (the KORAL study)
conducted to assess the design, acceptability, and feasi-
bility issues relevant to designing a surgical placebo-
controlled trial for the evaluation of the clinical and cost
effectiveness of arthroscopic lavage (washing out of the
knee space under general anaesthetic) for the manage-
ment of people with osteoarthritis of the knee in the
UK. Whilst the primary focus was on arthroscopic
lavage (and was written up in a separate monograph
[15]), the study highlighted a range of wider issues rele-
vant to the design and conduct of surgical placebo-
controlled trials in general, and it is those that we focus
on in this paper.
The KORAL study
Our group was commissioned by the UK National Insti-
tute for Health Research Health Technology Assessment
(NIHR HTA) Programme to design and conduct a
placebo-controlled trial to assess the clinical and cost
effectiveness of arthroscopic lavage for the management
of people with osteoarthritis of the knee in the UK. The
purpose of the trial was to confirm or refute the find-
ings of an earlier study conducted in the US by Moseley
and colleagues [16]. In the Moseley trial, patients had
been randomised to arthroscopic lavage, arthroscopic
debridement or placebo procedure and had found that
whilst all groups improved, no significant difference was
observed at follow-up between the placebo group and
either ‘active’ surgery group; the conclusion being that
observed benefit was due to the placebo effect. Whilst
the Moseley trial had been conducted with methodologi-
cal rigour, it had been conducted in a single US centre
by a single surgeon and the generalisability of the results
had been questioned by a number of authors [17-19].
Given that it was unclear whether an acceptable placebo
could be designed and delivered in a feasible manner,
the project first explored in an in-depth manner issues
around the design, acceptability and feasibility of a sur-
gical placebo for this trial (it is this in-depth study that
is presented in this paper).
This study, which was known as KORAL (Knee
Osteoarthritis: Role of Arthroscopic Lavage) had the fol-
lowing research questions (RQs) that were addressed in
a staged way in a series of sub-studies:
RQ1. Is there a need for a further placebo-controlled
trial of arthroscopic lavage for osteoarthritis of the
knee? If yes,
RQ2. Can an appropriate surgical and anaesthetic
placebo be designed for such a trial? If yes,
RQ3. Would key stakeholders find the proposed
placebo-controlled trial design acceptable? If yes,
RQ4. Would conducting such a multi-centre surgical
placebo-controlled trial be feasible in the UK?
Methods
The research was conducted in two main phases. Firstly,
an in-depth qualitative and quantitative exploration of
possible placebo designs and their acceptability to key
stakeholder groups (addressing RQs1-3) was conducted.
Secondly a formal pilot of the proposed trial design to
test feasibility (RQ4) was undertaken. Multi-centre
Research Ethics Committee (MREC) approval was
received separately for the two phases. Full details of the
methods used in this study were given in the clinical
monograph [15], however, brief details are provided
below.
Exploration of possible placebo designs and the
acceptability of a placebo-controlled trial to key
stakeholder groups
In the first phase, we particularly addressed: a) the per-
ceived scientific merit of further evaluation of arthro-
scopic lavage (including by placebo-controlled trial);
b) the choice of the placebo procedure, both surgical
and anaesthetic; and c) the likely acceptability of differ-
ent placebo-controlled trial designs to key stakeholder
groups including surgeons, anaesthetists, potential parti-
cipants and chairs of ethics committees.
We conducted focus groups with, and postal surveys
of, surgeons and anaesthetists; focus groups and inter-
views with people with osteoarthritis (potential trial
participants); and interviews with Chairs of MRECs
(Table 1). Focus group discussions were informed by a
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presentation from the project team on background
rates of arthroscopic lavage, details of the Moseley trial
(including the design, results and perceived criticisms)
and the project brief. Focus group discussions and
interviews were audio-tape recorded and transcribed.
Transcripts were analysed thematically using a modi-
fied Framework approach [20]. Within the focus
groups and interviews we used the term “placebo sur-
gery” (rather than possible alternatives such as “sham”
or “dummy” surgery) as early on in the research we
found that the choice of word could lead to different
perceptions, despite the rationale behind their use
being the same [15]. The term “placebo surgery” was
adopted in an attempt to describe as accurately as pos-
sible the intention behind the procedure ie, to maxi-
mise the mimic, whilst minimising the risk.
All members of the British Association of Surgeons of
the Knee and members of the British Association of
Orthopaedic Anaesthetists were surveyed for their opi-
nion. Permission was received from both Societies for
only a single mailing to members. Responses to the sur-
veys were summarised using simple descriptive statistics.
The final output of this first phase was the template
for a preferred trial design.
Formal pilot of the proposed trial design to test
feasibility
The second phase was a formal pilot of the preferred
trial design that had been developed in Phase One. The
formal pilot was conducted in two centres. Analysis of
the pilot data consisted primarily of descriptive statistics
including proportion of eligible patients randomised,
and reasons for refusing to take part in the trial.
Results
Need for proposed further evaluation of arthroscopic
lavage
From the focus groups and interviews, there was broad
acceptance across all stakeholder groups of the need to
find out more about the effects of arthroscopic lavage.
Surgeons expressed uncertainty about the overall effec-
tiveness of lavage. On the one hand some indicated that
there was some evidence to suggest that lavage might
offer at least short-term pain relief:
“if ... you end up washing the knee out, sometimes the
symptoms do improve and make it pseudo-working.
We had a lady recently, and she had a defect, and
she’s a lot better since we washed the knee out, that’s
three weeks ago now.” (Surgeon 1, Group C)
However, others commented that they often observed
their patients “all coming back” with continuing pro-
blems after the procedure, thus raising concerns about
the longer term and overall effectiveness of the
technique.
People with osteoarthritis of the knee also expressed
the need to find out definitively whether arthroscopic
lavage was effective. For example, one mentioned the
scientific uncertainty surrounding the effectiveness of
arthroscopic lavage, and another highlighted the need
for research into the long-term effectiveness of such sur-
gical procedures:
“Well, we have got to find out, you know, it has been
going on for years and years and no one has ever
found a complete answer so things have got to be
Table 1 Details of those who contributed to the focus groups, interviews and surveys
Study component Number who participated
Focus groups with health professionals:
• two surgeon focus groups at the 2005 British Orthopaedic Association meeting 16 surgeons
• one regional surgeon focus group 25 surgeons
• plenary discussion at the 2005 British Society of Orthopaedic Anaesthetists meeting 130 anaesthetists
• detailed focus group at the 2005 British Society of Orthopaedic Anaesthetists meeting 8 anaesthetists
• two regional focus groups with anaesthetists 50 anaesthetists
Focus group and interviews with people with osteoarthritis:
• two focus groups with members of the patient organisation Arthritis Care 7 people
• telephone interviews with patients on consultant waiting lists from two UK regional centres 15 people
Interviews with Chairs of UK MRECs:
• telephone interviews with MREC Chairs 6 MREC Chairs
Surveys of health professionals:
• postal survey of all members of the British Association of Surgeons of the Knee 382 surgeons
• postal survey of all members of the British Society of Orthopaedic Anaesthetists 398 anaesthetists
Note: 12 of the 13 UK MRECs which were in existence at the time of the research were invited to take part in the research. (To preserve their independence with
regard to any future ethics decisions about KORAL, the MREC that approved this part of the study was excluded from this component).
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tried, you know... If you want to advance that is what
you have to do."(Participant 1)
“I certainly think it [a trial of arthroscopic lavage] is
worthwhile because at the end of the day ...I don’t
think that people should undergo surgery unless it
was having some long term benefit to them ... it
should only be done when it is going to have a posi-
tive effect and a long lasting effect.” (Participant 2)
Although all the groups accepted there was a need to
find out more about the effects of arthroscopic lavage,
there was variation in opinion about how researchers
should investigate this and about whether it would be
acceptable to investigate the effectiveness of arthro-
scopic lavage using placebo surgery. This is discussed
below.
Design of a surgical placebo
Discussion within the surgeons’ focus groups concen-
trated mainly on the ways in which a placebo could
mimic arthroscopic lavage (the active surgery), whilst
ensuring that any risks of harm were minimised. The
consensus emerged fairly readily that three superficial
skin incisions were needed, that these should only pierce
the epidermis, and that any penetration of the knee cap-
sule should be avoided.
“No, you don’t have to do the dermis ... just enough
to make it bleed” (Surgeon 8, Group B)
Ensuring that penetration of the knee capsule did not
occur was promoted for two primary reasons: a) that it
would reduce the risk of any infection and b) it would
ensure that no form of lavage was inadvertently per-
formed:
“If you put the scope in you introduce fluid therefore
technically it becomes a lavage even if it’s a tiny
amount, doesn’t it?” [several yes’s round the table]
(Surgeon 7, Group C)
Within the anaesthetists’ focus groups, the question
about the most appropriate form of anaesthesia to
incorporate within a placebo procedure was more con-
tentious. Some anaesthetists objected to the ethics of
conducting any research that involved a placebo (see
acceptability section below), and did not feel comforta-
ble discussing the design of an anaesthetic for such a
procedure. However, a consensus eventually emerged
that the patients in both trial groups should receive the
same anaesthetic, and that this should be the regimen
the individual anaesthetists who participated in the trial
would customarily use for a simple arthroscopic proce-
dure (i.e. a general anaesthetic). They believed that this
would not only maximise the mimic of the active sur-
gery but would also minimise the risks to participants.
As they had more experience with general anaesthesia
in these cases, they believed it would be safer than a
technique using a combination of sedatives and analge-
sics as used in the Moseley trial (on the premise that it
was less risky for their patients), but was felt to be less
familiar and therefore less safe by our respondents:
“Hasn’t the starting point got to be, you should do
the same [as for the active surgery group] unless
there is a really good reason not to? And if the really
good reason is all about risk then you have to show
that their [the sedation procedure used by the Mose-
ley trial, on the grounds that it was of lower risk to
patients] intervention has less risk than the standard
full anaesthetic. I am convinced that that is not the
case. So therefore you should do the standard
straightforward general anaesthetic” (Anaesthetist 5,
Group B)
“Statistically, [the sedation procedure used by the
Moseley trial], is more dangerous than a general
anaesthetic [on the grounds that it was of lower risk
to patients]” (Anaesthetist 6, Group A)
Assuming that general anaesthesia was to be adopted,
the anaesthetists within the focus groups agreed that
inclusion should be restricted to low risk patients, as
defined by those who were American Society of
Anesthesiologists (ASA) grades 1 or 2 [21,22] - that is
“normal healthy patients” or “patients with mild sys-
temic disease” who had no other contraindication to
anaesthesia.
Acceptability of a surgical placebo-controlled trial
Views expressed by health professionals
Although none of the surgeons who took part in the
focus groups disputed the need for further investigation
of the effectiveness or otherwise of arthroscopic lavage,
there was extensive debate within the groups about
whether a placebo-controlled trial was necessary to gen-
erate new knowledge, and whether it was acceptable.
For example:
“It would be more ethically correct to compare doing
nothing to a lavage first and then look at the results
and see”... You don’t need to know the benefits of the
placebo, it’s irrelevant. When you make a clinical
decision, you have to decide whether it’s lavage or
not. And so all you need to know is benefit from
lavage and benefit from not doing anything and if
the benefit from the lavage is marginal, then you
don’t do lavage and that’s all that you need to
do..."(Surgeon 3, Group C)
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“What you need to do first is a decent study to actu-
ally look at conservative versus operative [manage-
ment] and then once you’ve done that decent study,
can you consider putting people at risk of placebo
operations” (Surgeon 10, Group C)
Other surgeons disagreed, however, arguing that there
was a methodological need for a placebo surgical trial
because: a) a placebo component is needed to detect a
small difference between the groups; and b) that a pla-
cebo is needed to attempt to disentangle what (if any)
aspect of the arthroscopic lavage procedure is having a
positive effect.
Overall, the health professionals tended to be split
between: a) those who were strongly opposed to the
inclusion of a placebo surgical arm on the grounds that
it could lead to potential harm among individuals who
could expect no personal benefit; and b) those who
were in favour as that they believed the small risks that
relatively few people in a placebo surgery trial arm
would be exposed to were justified (because they were
outweighed by the potential benefit to future patients
and broader society of helping to ensure either that a
demonstrably effective surgical procedure was used or
that a demonstrably ineffective procedure was stopped).
Those opposed to the inclusion of a placebo surgical
arm expressed strong personal views on their perceived
ethics of such an approach:
“As an anaesthetist I would not anaesthetise someone
for sham surgery. I just couldn’t! I just think it’s
immoral and unethical ... I mean it’s as simple as
that, you wouldn’t do it”. (Anaesthetist 1, Group A)
“The number who will do this willingly will be very,
very small, most of my colleagues would say - no
you’re joking”...(Anaesthetist 6, Group A)
On the other hand, those in favour pointed to the
benefit to future patients and the desire to let patients
rather than clinicians decide what was best for them:
“If the patient is prepared to accept the risk in order
to have the operation and they are prepared to enter
the trial on the understanding that they might not
have an operation, are we all being a bit precious [ie,
overly protective]?” (Anaesthetist 4, Group B)
“34,000 people ... per year are having a procedure
which has no proof to it. So you’re already doing the
ladies with the [weak] hearts, putting the tourniquets
up, giving them the drugs for absolutely no proven evi-
dence... at the moment if there are 34,000 of these pro-
cedures being done and we are exposing that number
of patients to all the risks of anaesthesia then we need
to know the answer” (Anaesthetist 5, Group A)
Some individuals who were personally in favour of
using a placebo were concerned that professional regula-
tors would not be (with consequent implications for
their potential participation):
“Interesting though ... I accept [it] is completely logi-
cal that the needs of the many outweigh the needs of
the few but the GMC [General Medical Council]
doesn’t see that do they? The GMC make it very spe-
cific in their guidance to us that it is the needs of the
individual which is your primary concern” (Anaesthe-
tist 4, Group B)
One hundred and seventy three (43%) members of the
British Association of Surgeons of the Knee responded
to the survey as did 136 (34%) members of the British
Society of Orthopaedic Anaesthetists (Table 2). Findings
from the surveys supported the insights observed in the
focus groups. The surveys showed that a sizeable per-
centage of health professionals (51% of surgeons and
40% of anaesthetists) were supportive of a trial with a
placebo arm being mounted. The survey also showed
that 43% of surgeons would personally consider taking
part in such a trial as would 47% of anaesthetists. It was
interesting to note that although some anaesthetists
were personally not in favour of a placebo arm being
involved they would, however, consider taking part if
their surgeon colleagues wished to take part.
As part of the survey we also asked surgeons and
anaesthetists for their views on the appropriate rando-
misation ratio for any potential trial. The majority
favoured an allocation ratio of 1:1:1 to arthroscopic
lavage, placebo surgery or non-operative management
(60% of surgeons, 46% anaesthetists) or had no prefer-
ence (25% surgeons, 41% anaesthetists), rather than a
2:1:1 ratio (10% surgeons, 10% anaesthetists) or some
other ratio (5% surgeons, 3% anaesthetists).
Views expressed by people with osteoarthritis
In their focus groups and interviews, people with osteoar-
thritis echoed the need to find out more about the effects of
arthroscopic lavage, and many of our sample indicated that
they would consider taking part in a placebo-controlled trial.
Two participants also discussed how, from a research point
of view, including a placebo surgical component could be
very useful. They drew on the information presented by the
interviewers and explained that a placebo arm would help
check whether any perceived benefit from arthroscopic
lavage was due to a placebo effect. For example:
“... I would say it is important to have the placebo in
it because if there is a sort of mind set that it does
help to heal you, I mean it has been proven over the
years that placebos do benefit in certain things.”
(Participant 1)
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“... I think the placebo group is a very good idea
because it can almost fool somebody into thinking
they have had a procedure when they haven’t and
basically prove to some people that you think you are
better because you think you have had this procedure
but in fact you didn’t have any treatment done at
all."(Participant 2)
However, a few people in our sample thought involve-
ment in a placebo-controlled trial would not be appro-
priate for them:
“if I was informed then that I had had the placebo
and I realised that I had still got the pain I would be
so furious...so angry” (Participant 14)
Those who were willing to take part openly acknowl-
edged the risks of general anaesthetic and endorsed the
need for anaesthetists to select only those at low risk.
For example:
“... there is always, albeit I think it is quite small, risk
of complications with anaesthesia ... there can be
problems but they are very few and far between and
if the right patients are selected then I don’t think
there would be any problems.” (Participant 2)
Views expressed by Chairs of Ethics Committees
The Chairs of Ethics Committees highlighted a range of
issues that should be addressed in any ethics application,
eg, justifying the need for the placebo and the general
anaesthetic, plans for minimising risks to patients, etc.
Whilst they acknowledged that a surgical placebo-
controlled trial would not simply be dismissed on prin-
ciple, they predicted a “rough journey” through the
ethics process for any such proposal:
“... I would have to think extremely laterally to envi-
sage that this would get through without a very
rough journey on the way ... We have one committee
in particular which anything placebo ... is evaluated
with a fine tooth comb and there we’re talking little
white tablets... The prospect of using a surgical
approach I think raises the stakes enormously”
(MREC 3)
“...I would think that in conclusion it’s probably the
general anaesthesia that will cause ethics committees
the most problems because then they will say now is
this really too much of a risk to be giving somebody a
general anaesthetic for nothing... I can see everybody
say, ‘Oh oh no way, not general anaesthetics’”
(MREC 1)
“ ... I’d want a very robust justification for tackling
the equipoise in this rather risky, in this potentially
risky way. I think any self-respecting Committee
that is the question they would ask. I would cer-
tainly be weighed by what risks our anaesthetic col-
leagues thought fair. I mean you’ve got to, you can’t
negate the risk... If the study is going ahead, there is
a risk, you can’t negate it. I think I’d want evidence
that the risks had been fully considered and mini-
mised... my experience is [that] anaesthetists are a
very ethical lot indeed... and they serve as a very
useful counterbalance to the surgeons ...I can see
the surgeons are faced with people in awful, intract-
able pain and they want to do something about it”
(MREC 4)
Development of a preferred design to take to pilot study
The final output of the exploratory phase was to develop
a preferred trial design to take forward to a formal pilot.
The preferred design was developed from the insights
gained from the exploratory work undertaken with sur-
geons anaesthetists and potential participants. The fina-
lised design was agreed with the funder and was as
follows - patients were to be eligible for inclusion if they
were: adults aged 18 years or older with radiological evi-
dence of osteoarthritis of the knee who might be consid-
ered for arthroscopic lavage; at low risk for general
anaesthesia - ASA grades 1 and 2; and able to give
informed consent. Following consent, patients would be
randomly allocated to: arthroscopic lavage (with or with-
out debridement as deemed clinically necessary); pla-
cebo surgery; or non-operative management (fuller
details of the three intervention arms are presented in
Figure 1). No change in treatment (other than in analge-
sia use) was to be allowed in any of the randomised
groups for a period equivalent to three months after
randomisation.
Table 2 Attitudes of surgeons and anaesthetists to a placebo controlled trial
Surgeons Anaesthetists
Number of questionnaires despatched 382 398
Number (%) of questionnaire returned 173 (45%) 136 (34%)
Potential trial of arthroscopic lavage vs placebo surgery vs conservative management: n/N (%) n/N (%)
• Supportive of trial with placebo arm being mounted 85/168 (50.6) 54/135 (40.0)
• Would consider taking part in a trial with a placebo arm 71/166 (42.8) 63/134 (47.0)
• Would encourage a friend or family member to sign up for a trial with a placebo arm 67/168 (39.9) 48/135 (35.6)
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For those randomised to some form of surgery, the
type of surgery (whether arthroscopic lavage or placebo)
was not to be revealed until the patient had been anaes-
thetised and was in the operating theatre. After surgery,
discussions with patients would follow a pre-agreed
approach: “you know that I cannot tell you whether you
had the active surgery or the placebo, but I can tell you
that the procedure went well and we will now need to
see how well this helps your knee“. This approach was to
be maintained during follow-up clinic appointments.
   Arthroscopic lavage (with or without debridement as clinically indicated):
? Day case procedure under general anaesthesia.   
? (Depending on the surgeon’s standard practice) a tourniquet to be used on 
the upper thigh, with either formal exsanguination of the leg or elevation. 
? After sterile preparation and draping, arthroscope to be inserted into the 
knee joint via a lateral parapatellar stab arthrotomy, and probe inserted via a 
medial parapatellar tendon stab arthrotomy.  Drainage cannula to be 
inserted via a further lateral suprapatellar arthrotomy.   
? Ordered inspection of the joint and the intraarticular structures follows.   
? Joint to be lavaged with ? 3 litres warm saline and loose debris washed out.  
Further debridement to remove larger loose bodies and trim frayed meniscal 
edges, minor tears or osteophytes to be carried out at the surgeon’s 
discretion.  Irrigation fluid to be drained from the knee and the arthroscope 
removed.   
? Incisions to be sutured or closed with suture strips (as per clinical 
judgement), and dressed.  Local anaesthesia to be inserted into the knee 
space at the end of surgery for post operative analgesia. 
   
RANDOMISATION* 
    
Placebo surgery:
? Informed by the extensive discussions with the surgeons and anaesthetists.   
? Preparation and initial management as per the arthroscopic lavage group ie 
day case procedure under general anaesthesia and, depending on the 
surgeon’s standard practice, a tourniquet to be used on the upper thigh, with 
either formal exsanguination of the leg or elevation. 
? After sterile preparation and draping, three 1cm skin incisions, penetrating 
only the epidermis, to be made in the same medial and lateral parapatellar 
tendon and lateral suprapatellar positions as for a standard arthroscopy.  No 
penetration of the knee space.   
? Incisions to be sutured or closed with suture strips (as per clinical judgement) 
and dressed.  Local anaesthesia to be inserted into the incisions for post 
operative analgesia.   
? Patients to be kept in theatre for a similar time to that required for lavage 
(approximately 20 minutes). 
   
    
   Non-operative management with specialist reassessment:
? Specialist reassessment to be undertaken and recommendation of care 
(other than arthroscopic lavage) made, taking into account previous 
management.  Specific management regimen at discretion of enrolling 
surgeon (details to be recorded).   
*specific form of surgery only revealed in theatre  
Figure 1 Schematic of pilot.
Campbell et al. Trials 2011, 12:50
http://www.trialsjournal.com/content/12/1/50
Page 7 of 12
Feasibility of the proposed placebo-controlled design
Ethics approval
Gaining ethics approval for the pilot study was difficult
and took nine months. The initial application for the
pilot phase was rejected. Two main concerns were
raised: a) the potential inclusion of surgeons who would
not routinely offer arthroscopic lavage; and b) the
potential inclusion of centres where arthroscopic lavage
was being phased out and was no longer a routine treat-
ment choice. We appealed against this decision on the
counter-arguments that: a) surgeons who would never
consider arthroscopic lavage would not agree to take
part in the trial, so one could assume that all patients
recruited from surgeons who agreed to participate in
the trial would have a possibility (albeit sometimes low)
of having been offered lavage had the trial not been in
place; and b) it could have been uncertainty of effective-
ness of arthroscopic lavage rather than certainty about
the lack of effectiveness that led centres to stop under-
taking routine arthroscopic lavage. Thus including those
centres where surgeons who still wished to find out
whether lavage was truly effective was a further justifica-
tion for the research, rather than an ethical objection to
it. The second MREC which heard our appeal approved
the pilot, subject to our considerably extending the
patient information leaflet (which we duly did).
Local authorisations
Despite ethics committee approval, the pilot subsequently
required major discussion and negotiation at each indivi-
dual centre before local clinical approvals could be
obtained. Some of the arguments discussed at the ethics
committee were raised again at local level and the fact that
ethics approval had been granted did not mean that clini-
cians would automatically accept that the process was
ethical. There were also concerns about who would pay
for any placebo procedure and about indemnity arrange-
ments. Despite extensive negotiations full local approval
was not achieved for one of the two pilot centres within
the four-month timeframe of the pilot study (a number,
but not all, of the authorisations were successfully in
place). In the centre where the pilot did receive approval,
the local authorisation process also led to caveats being
placed on the delivery of the trial locally (eg, the restriction
that only consultant anaesthetists take part).
Delivery of the pilot design
Eight clinics were held over the course of the pilot phase,
drawing patients identified as potentially eligible for the
trial by screening referral letters sent by the patients’
General Practitioners (GPs). Forty nine patients were
invited to attend. Of the 40 patients who attended, 13
were eligible and nine consented to take part (Figure 2).
Six were randomised to some form of surgery and three
to non-operative management. Two of the six patients
randomised to surgery subsequently withdrew from the
pilot prior to surgery. Both cited anxieties about the pos-
sibility of receiving placebo rather than active surgery
among their reasons for withdrawal. One also highlighted
concerns about Methicillin-resistant Staphylococcus Aur-
eus (MRSA).
The three patients randomised to non-surgical man-
agement were reassessed by the treating clinician on the
same day as the recruiting clinic, following randomisa-
tion. All three were advised on analgesic use. Two parti-
cipants were given lifestyle modification advice and
exercise information. The use of a walking stick was
suggested to one participant but this was declined. Two
participants were advised to use an elastic knee brace
and one on the use of heat or ice.
One surgical session took place which involved one
active and one placebo procedure (the two remaining
surgical patients were managed outwith the framework
of the pilot - see below). The patient allocated to active
procedure underwent arthroscopic lavage with three
litres of saline (debridement was not required) and the
procedure was completed as per protocol. The placebo
surgery was also undertaken successfully as per protocol.
The surgeon and anaesthetist reported that the practi-
calities of both active and placebo surgery presented no
major problems. Operating theatre staff did, however,
express some concern when it was revealed that a
patient was to receive placebo surgery (despite the fact
that they had previously been fully informed of the nat-
ure of the trial). Through the two month follow-up
questionnaire, neither patient reported that they thought
they had undergone placebo surgery.
Decision whether to progress to a large-scale trial
Towards the planned end of the pilot, the funders
reviewed our study findings to decide whether to con-
tinue seamlessly into the conduct of a full-scale trial.
They concluded that a surgical placebo for arthroscopic
lavage could be successfully designed, was generally
acceptable to the range of stakeholder groups (although
a few held strong views against the use of a surgical pla-
cebo under any circumstances), but faced considerable
feasibility barriers when trying to conduct the trial in
practice. In the light of these findings, the funders
decided that the anticipated time, energy and cost
required to bring multiple centres on board to recruit
sufficient numbers (approximately 800 would be
required) to a definitive large-scale trial over a sustained
period of time was not justified (especially against a
background of a gradual, albeit slow, decline in arthro-
scopic lavage [23]). As two of the pilot patients were
still awaiting their surgery at the time of this decision,
and it was as yet unclear if this was to be active or pla-
cebo surgery, it was deemed inappropriate to continue
their management under pilot conditions and their man-
agement was reviewed outside the pilot framework.
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Discussion
Our study illustrated that a surgical placebo for arthro-
scopic lavage could be designed that was acceptable to a
sizeable proportion of people across the range of stake-
holder groups (although a few held strong views against
the use of a surgical placebo under any circumstances),
but conducting such a trial in practice would face con-
siderable feasibility issues. Our study also illustrated well
the opposing and often strongly held opinions that are
held about placebos in surgery, the ethical issues that
underpins this controversy, and the challenges of
mounting such a trial that exist even when ethics com-
mittee approval has been granted.
Issues of ethical and scientific acceptability of a placebo
design in surgery
There was widespread acceptance in our study that
further investigation was required into the effectiveness
of arthroscopic lavage. Whether that investigation
should or should not include a placebo-controlled
design generated much wider discussion.
Commentators agree that the ethical principles appro-
priate to all clinical research must be satisfied as a mini-
mum when considering a placebo-controlled design.
These principles are that the study must: a) have scienti-
fic merit, b) be acceptable to participants in terms of the
risk-to-benefit ratio of participation and c) respect the
autonomy of participants by enabling them to determine
whether they should participate [24]. In the qualitative
components of our study participants raised and dis-
cussed these factors for the case of arthroscopic lavage.
The scientific merit of the proposed study and the need
for informed consent were readily accepted. Whether
the proposed study design provided an acceptable bal-
ance of risks and potential benefits for participants gen-
erated much wider debate.
The discussion of an acceptable risk-to-benefit ratio in
a placebo-controlled study is not straightforward. As
Horng and Miller [25] argue, the risks must be consid-
ered in the context of alternative study designs to
answer the research question - could an evaluation of
arthroscopic lavage be conducted without the use of a
FEASIBILITY CHECKLIST  
FOR
SURGICAL PLACEBO CONTROLLED TRIALS  
Infrastructure required to proceed with trial:  
? Have enough surgeon/anaesthetist pairs in every centre agreed to take part? ?
? Has management approval been obtained at all necessary levels eg anaesthetic 
committee, divisional management? 
?
? Have commissioners agreed to pay for placebo procedures to be undertaken? ?
? Are appropriate indemnity arrangements in place? ?
? Have the extended teams eg theatre teams been briefed and agreed that they are 
willing to participate? 
?
Evidence that trial will progress once set up:  
? Have patients shown that they are willing to participate in such a trial? ?
? Have patients shown that they are willing to remain in the trial if they are allocated to 
the possibility of a placebo procedure? 
?
Figure 2 Feasibility checklist for surgical placebo controlled trials.
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placebo control and without compromising scientific
rigour? The subjective measurement of the primary out-
come in our study (patient reported pain) was recog-
nised to be prone to bias in an open trial design (ie,
when people would know which intervention they had
been randomised to) [26], and it was considered impos-
sible to maintain an open trial sufficiently long for any
placebo effect to have dissipated, and as such the inclu-
sion of a placebo control was deemed to maximise
scientific rigour.
An additional consideration in the risk-to-benefit ratio
for participants is the nature of the proposed placebo -
how “risky” the proposed placebo is perceived to be.
A placebo must be able to mimic the intervention under
evaluation, but minimise the risks to those who might
take part in the trial. Edwards et al suggest that percep-
tions of acceptability of placebo are likely to vary
depending on the nature of the placebo in question [27].
In our study, agreement of the choice of placebo surgi-
cal procedure proved easier than the method of anaes-
thesia. The surgical approach chosen (three small skin
incisions) was both a satisfactory mimic and had low
intrusiveness and thus required little debate. However,
the use of general anaesthesia, while an excellent mimic,
was more intrusive and as such generated much greater
discussion, and was the factor that caused most discus-
sion with local decision-makers when seeking formal
approval to conduct the pilot. It is interesting to note,
however, that the content experts (ie, the anaesthetists)
contended that the use of a general anaesthetic would
be safer (because this is the technique which they used
routinely and with which they have the greatest experi-
ence) than a supposedly less intrusive alternative, such
as a form of analgeso-sedative regimen, with which they
were less familiar. The wider literature supports this,
suggesting that the success of a procedure is directly
related to the number of procedures undertaken by that
individual [28].
Further evidence of the controversial nature of the pla-
cebo design was the need to go to an appeal before the
pilot trial received ethics committee approval, despite
evidence of support from a range of surgeons, anaesthe-
tists and potential participants. In response to the ethical
debate raised by the Moseley trial [16], the American
Medical Association produced a set of principles under
which a placebo-controlled trial in surgery would be con-
sidered ethical [29]. These principles outlined: that surgi-
cal “placebo” controls should be used only when no other
trial design will yield the requisite data; that particular
attention must be paid to the informed consent process
when enrolling participants in such trials; that the use of
surgical “placebo” controls may be justified when an
existing, accepted surgical procedure is being tested for
efficacy (but that it was not justified when testing the
effectiveness of an innovative surgical technique that
represents only a minor modification of an existing,
accepted surgical procedure); and that when a new surgi-
cal procedure is developed with the prospect of treating a
condition for which no known surgical therapy exists,
using surgical “placebo” controls may be justified, but
must be evaluated in light of whether the current stan-
dard of care includes a non-surgical treatment and the
benefits, risks and side-effects of that treatment. Our
experience suggests that these principles remain relevant;
but, for a placebo-controlled trial to be conducted suc-
cessfully, it is clear that it must not only be an ethically
and scientifically acceptable course of action but must
also be a feasible course of action.
Issues around feasibility of a placebo-controlled trial in
surgery
Randomised controlled trials in surgery are well-known
to be difficult to design and often suffer from recruit-
ment problems [30,31] and adding a placebo component
to the design adds to this complexity. Our study also
faced a number of practical hurdles before it com-
menced recruitment and it proved impossible to sur-
mount all of these in one of the two pilot centres within
the four-month timeframe of the pilot. We found that:
a) stakeholders in each trial centre needed to be fully
briefed and any ethical and practical concerns resolved
prior to trial commencement; b) that arrangements
needed to be put in place to cover the costs of the pla-
cebo before the trial could go ahead; and that c) appro-
priate indemnity arrangements needed to have been
instituted. The crucial importance of local stakeholders
and gatekeepers has been outlined by a number of
authors and the need to develop explicit recruitment
and communication strategies identified [32,33].
Our study confirmed that recruitment to a surgical
placebo-controlled trial is achievable - nine of 13 eligible
patients approached agreed to join the trial - and the
study also demonstrated that blinding of participants
receiving surgery was successfully maintained. However,
two of the six allocated to surgery subsequently with-
drew before surgery citing concerns about the possibility
of receiving placebo surgery and risks associated with
hospitalisation as reasons. This raises questions about
the potential influence of a placebo arm on retention
rates in surgical trials.
This range of feasibility issues is likely to be faced by
anyone considering a placebo-controlled surgical trial,
and a checklist of appropriate issues that trialists should
consider is presented in Figure 2.
Strengths and weaknesses of the study
Surgical placebos are controversial and this is one of the
few studies to have explored empirically the attitudes
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and perceptions of stakeholders on this important issue.
In addition it sought to reflect the perspectives of a
wide range of stakeholders including surgeons, anaesthe-
tists, potential participants and ethics committee chairs.
It also ensured UK-wide coverage of opinions through
the professional surveys (although response rates were,
like those for other surveys among health professionals,
quite low), and this provides reassurance that the results
are reflective of the current range of opinion on the
issue of surgical placebos in general. Similarly the invol-
vement of multiple centres in the research was a
strength, as previous studies of placebos have often been
conducted in a single centre setting. This was one of the
key criticisms of the Moseley trial as it only involved a
single surgeon in a single centre.
We recognise, however, that our study concentrated
on a relatively minor surgical procedure and that the
results may have been different if we had been trying to
design a placebo for a more invasive procedure which
would have required a larger surgical incision or more
complex anaesthetic or a higher risk of major complica-
tions. We anticipate that in those circumstances consen-
sus on both the design and acceptability of the placebo
would have been harder to achieve and that recruitment
to the study may have been lower. In addition, the num-
ber of patients recruited to the pilot study was small;
limiting the conclusions we can draw from their
responses. However, we are confident that the range of
issues which require to be considered when planning a
placebo-controlled trial in surgery were encountered in
this study.
Conclusions
Our study showed in principle, a placebo-controlled trial
of arthroscopic lavage could be conducted in the UK,
albeit with difficulty. It highlighted well that not only
does a placebo-controlled trial in surgery have to be
ethically and scientifically acceptable but that it also
must be a feasible course of action.
In the light of our experience, the place of placebo-
controlled surgical trials seems likely to be very limited.
Our study suggests that the following conditions would
need to be satisfied:
a) alternative designs would provide inferior (and
potentially biased) results, particularly where the pri-
mary outcome is of a subjective nature and blinding
cannot be sustained beyond the time of any placebo
effect;
b) a placebo surgical procedure and type of anaes-
thesia can be devised which adequately mimic the
active intervention with a level of intrusiveness and
risk that is acceptable to the surgeons and anaesthe-
tists who would take part in the trial, and to ethics
committees, research governance assessors and
potential participants;
c) appropriate practical arrangements can be insti-
tuted in local centres to ensure that the delivery of
such a design would be feasible;
d) sufficient numbers of potential participants (after
assessment of clear descriptions and careful explana-
tions in patient information leaflets of the advan-
tages and disadvantages of taking part) judge for
themselves that the risk-to-benefit ratio of participa-
tion is acceptable to them; and
e) levels of compliance with the allocation are suffi-
ciently high to sustain scientific rigour.
Those who would rule out the use of surgical placebos
in these circumstances come up against two difficult
questions: 1) What about the apparent acceptability of
the methodology to potential participants? and 2) What
do we tell people with this painful, chronic and progres-
sive condition why a procedure that is unproven is
being offered or why a potentially effective intervention
has been discarded?
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